PT  - JOURNAL ARTICLE
AU  - Gibbons, Don L.
AU  - Byers, Lauren Averett
TI  - A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow
AID  - 10.1158/2159-8290.CD-14-0791
DP  - 2014 Sep 01
TA  - Cancer Discovery
PG  - 991--994
VI  - 4
IP  - 9
4099  - http://cancerdiscovery.aacrjournals.org/content/4/9/991.short
4100  - http://cancerdiscovery.aacrjournals.org/content/4/9/991.full
SO  - CANCER DISCOVERY2014 Sep 01; 4
AB  - Summary: Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. Cancer Discov; 4(9); 991–4. ©2014 AACR. See related article by Janjigian et al., p. 1036